Hypomethylation Agent (HMA)

Phase 1

BBeOne Medicines

Hypomethylation Agent (HMA) is one of 2 therapeutic programs targeting Myeloid Malignancy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Myeloid MalignancyRecruiting

Myeloid MalignancyPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Myeloid Malignancy

#DrugCompanyPhaseTrials

Hypomethylation Agent (HMA)

BBeOne Medicines

Phase 1

1 2

BG-75202

BBeOne Medicines

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Myeloid Malignancy

NCT07619287

Clinical

Trials by Indication[1]

Myeloid Malignancy1 trial

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies

Recruiting·BBeOne Medicines·Phase 1·NCT07619287·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hypomethylation Agent (HMA). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hypomethylation Agent (HMA). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: BBeOne Medicines

Hypomethylation Agent (HMA)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Myeloid Malignancy1 trial

References

Drug Info

Quick Facts

Related News